Ziltivekimab not checked
Novo Nordisk · COR-001 · MEDI5117
FollowEvery change as it happens, and a Monday email
Trials
5 active
11 in total · 5 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Zilitivekimab will be administered subcutaneously once-monthly.”In the company’s words, NCT06200207 on ClinicalTrials.gov
- Tested for
- Acute Myocardial Infarction (AMI) (2 trials), Heart Failure, Systemic Inflammation, Cardiovascular Risk, Coronary Artery Disease, Coronary Atherosclerosis of Native Coronary Artery, Myocardial Infarction
- Main trialPhase 3
- “The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.”In the company’s words, NCT06200207 on ClinicalTrials.gov
- Other names
- COR-001 · MEDI5117
Other drugs for Acute Myocardial Infarction (AMI)
- InclisiranNovartis · Phase 3
- MLC1501Moleac Pte Ltd. · Phase 2/3
- ClazakizumabCSL Behring · Phase 2/3
- PelacarsenNovartis · Phase 3
- PacibekitugNovartis · Phase 3
- OlpasiranAmgen · Phase 3
Coming up3
- 29 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 1 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- 14 Nov 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 1 Oct 2026 | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | |
| Phase 3Active, not recruiting | 29 Jan 2027 | ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | |
| Phase 3Recruiting | 1 Sep 2028 | Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction | |
| Phase 3Recruiting | 14 Nov 2028 | A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack | |
| Phase 3Terminated | 3 Sep 2026 | A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | |
| Phase 2Completed | 26 Jun 2020 | Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition | |
| Phase 2Completed | 3 Aug 2021 | Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan. | |
| Phase 1/2Completed | 11 Dec 2018 | Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001 | |
| Phase 1Terminated | 28 Feb 2014 | Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients | |
| Phase 1Completed | 12 Jun 2024 | A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation | |
| Phase 2/3Authorised | not given | Specifying the anti-inflammatory effects of ziltivekimab with diverse imaging modalities and in-depth cellular phenotyping (SPIDER) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026